| 0.2851 -0.065 (-18.5%) | 03-24 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.38  |
1-year : | 0.49 |
| Resists | First : | 0.33 |
Second : | 0.41 |
| Pivot price | 0.24 |
|||
| Supports | First : | 0.18 | Second : | 0.15 |
| MAs | MA(5) : | 0.21 |
MA(20) : | 0.24 |
| MA(100) : | 1.95 |
MA(250) : | 7.12 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 17.4 |
D(3) : | 16.7 |
| RSI | RSI(14): 27.4 |
|||
| 52-week | High : | 20.79 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MTP ] has closed above bottom band by 23.2%. Bollinger Bands are 92.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.23 - 0.23 | 0.23 - 0.23 |
| Low: | 0.2 - 0.2 | 0.2 - 0.2 |
| Close: | 0.21 - 0.22 | 0.22 - 0.22 |
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Thu, 11 Apr 2024
Midatech Pharma Rallies On Positive MTX102 Results - AOL
Fri, 24 Mar 2023
Midatech Pharma PLC Announces Results of General Meeting - Yahoo Finance
Wed, 15 Feb 2023
Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker Change - Yahoo Finance
Tue, 03 Jan 2023
BIOAF: Merger with Midatech Pharma - Yahoo Finance
Thu, 09 Jun 2022
Midatech Pharma PLC (NASDAQ: MTP) Receives Fast Track Designation for MTX110 for recurrent Glioblastoma ... - BP Journal
Wed, 23 Jun 2021
Midatech Pharma Plc (NASDAQ: MTP) Achieves Breakthrough In In-vitro Data Demonstrating The Potential of Q ... - BP Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 489640 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.35e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 169.3 % |
| Return on Equity (ttm) | -52.5 % |
| Qtrly Rev. Growth | 645000 % |
| Gross Profit (p.s.) | 13.68 |
| Sales Per Share | -78.26 |
| EBITDA (p.s.) | 473770 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.03 |
| Dividend | 0 |
| Forward Dividend | 21220 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2020-03-02 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|